Stoke Therapeutics Net Income Over Time
| STOK Stock | USD 32.40 1.92 6.30% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Stoke Therapeutics Performance and Stoke Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 1.172 | Return On Assets | Return On Equity |
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Stoke Therapeutics and related stocks such as Intellia Therapeutics, Upstream Bio, and Ardelyx Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (12.4 M) | (31.6 M) | (67.5 M) | (85.3 M) | (99.5 M) | (125.6 M) | (259.7 M) | (474.2 M) | (481.2 M) | (519 M) | (467.1 M) | (443.8 M) |
| UPB | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (20.5 M) | (62.8 M) | (56.5 M) | (59.4 M) |
| ARDX | (9.8 M) | (9.8 M) | (9.8 M) | (6.6 M) | (3.2 M) | (29.6 M) | (112.4 M) | (64.3 M) | (91.3 M) | (94.9 M) | (94.3 M) | (158.2 M) | (67.2 M) | (66.1 M) | (39.1 M) | (35.2 M) | (37 M) |
| SYRE | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (11.3 M) | (21.7 M) | (27.2 M) | (44.3 M) | (78.3 M) | (80.9 M) | (65.8 M) | (83.8 M) | (338.8 M) | (208 M) | (187.2 M) | (177.9 M) |
| WVE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (5.2 M) | (19.2 M) | (55.4 M) | (102 M) | (146.7 M) | (193.6 M) | (149.9 M) | (122.2 M) | (161.8 M) | (57.5 M) | (97 M) | (87.3 M) | (91.7 M) |
| ZYME | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (19.2 M) | (33.8 M) | (10.4 M) | (36.6 M) | (145.4 M) | (180.6 M) | (211.8 M) | 124.3 M | (118.7 M) | (122.7 M) | (110.4 M) | (115.9 M) |
| PHVS | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (9 M) | (29.6 M) | (42.7 M) | (76.3 M) | (100.9 M) | (134.2 M) | (120.8 M) | (114.8 M) |
| NVAX | (5.5 M) | (19.4 M) | (28.5 M) | (52 M) | (82.9 M) | (156.9 M) | (280 M) | (183.8 M) | (184.7 M) | (130.1 M) | (427.5 M) | (1.7 B) | (657.9 M) | (545.1 M) | (187.5 M) | (168.7 M) | (177.2 M) |
| BCRX | (6.9 M) | (56.9 M) | (39.1 M) | (30.1 M) | (45.2 M) | (43 M) | (55.1 M) | (65.8 M) | (101.3 M) | (108.9 M) | (182.8 M) | (184.1 M) | (247.1 M) | (226.5 M) | (88.9 M) | (80 M) | (84 M) |
Stoke Therapeutics and related stocks such as Intellia Therapeutics, Upstream Bio, and Ardelyx Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Stoke Therapeutics financial statement analysis. It represents the amount of money remaining after all of Stoke Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Stoke Therapeutics | STOK |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 45 Wiggins Avenue, |
| Exchange | NASDAQ Exchange |
USD 32.4
Check out Stoke Therapeutics Performance and Stoke Therapeutics Correlation. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Stoke Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.